1,894 reports of this reaction
4.2% of all LAMIVUDINE ORAL reports
#1 most reported adverse reaction
VIROLOGIC FAILURE is the #1 most commonly reported adverse reaction for LAMIVUDINE ORAL, manufactured by Apotex Corp.. There are 1,894 FDA adverse event reports linking LAMIVUDINE ORAL to VIROLOGIC FAILURE. This represents approximately 4.2% of all 44,876 adverse event reports for this drug.
Patients taking LAMIVUDINE ORAL who experience virologic failure should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
VIROLOGIC FAILURE is moderately reported among LAMIVUDINE ORAL users, representing a notable but not dominant share of adverse events.
In addition to virologic failure, the following adverse reactions have been reported for LAMIVUDINE ORAL:
The following drugs have also been linked to virologic failure in FDA adverse event reports:
VIROLOGIC FAILURE has been reported as an adverse event in 1,894 FDA reports for LAMIVUDINE ORAL. This does not prove causation, but indicates an association observed in post-market surveillance data.
VIROLOGIC FAILURE accounts for approximately 4.2% of all adverse event reports for LAMIVUDINE ORAL, making it one of the most commonly reported side effect.
If you experience virologic failure while taking LAMIVUDINE ORAL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.